

EP PerMed Strategic Research and Innovation Agenda (SRIA) and Draft Proposal Presentation

Monika Frenzel

Agence National de la Recherche, ANR

EP PerMed Drafting Group


Strategic Research and Innovation Agenda (SRIA)

General context

- All European Partnerships have to develop a **SRIA**
- The **EP PerMed proposal** will be directly connected/refer to the **SRIA**
- The **EP PerMed activities (e.g. Joint Transnational Calls, and other activities as trainings, events, etc.)** will be based on the **SRIA** and **EP PerMed proposal**

EP PerMed SRIA and Proposal development - timeline


SRIA



SRIA Update
~2024

Proposal

incl. the
Annual Work
Plan (AWP 2024)



dg: EP PerMed drafting group and EC/MS delegates; ToA: Triplets of Action; GA: Grant Agreement, CA: consortia agreement;
WG: EP PerMed proposal writing group; JTC: Joint Transnational Call; [SB: Steering Board and Sec: Secretariat ICPerMed]

START end of 2023

European Partnership for Personalised Medicine - EP PerMed

Strategic Research and Innovation Agenda (SRIA) – concept developed

The SRIA will address for example the following topics:

- Personalised Medicine related **research** in all related areas
- **Innovation** system and Personalised Medicine
- The **implementation** setting and Personalised Medicine
- Regional and international perspectives of PM
- Framework, infrastructures and data access for PM approaches


European Partnership for Personalised Medicine - EP PerMed

Strategic Research and Innovation Agenda (SRIA) – concept developed



EP PerMed

European Partnership
for **Personalised Medicine**



European Partnership for Personalised Medicine - EP PerMed

Strategic Research and Innovation Agenda (SRIA) – content development – 1st steps

The **SRIA** will identify gaps, needs and challenges as well as opportunities and visions which need to be addressed, overcome or reached to foster PM for the benefit of patients and citizens within sustainable health systems.

Process:

- Expertise of all involved initiatives & partners and existing strategic documents
- Organisation of activities to gather information and ideas for EP PerMed and its SRIA:
 - Around **70 interviews** with international PM experts and stakeholders were completed by the Drafting Group
 - So called: “**Triplets of Action, short ToA**” were identified
 - An **Online Consultation** with the 1st set of 47 ToA was performed (12/22)

Triplets of Action (ToA)

General structure for the « Triplets of Action, ToA »

| | |
|-----------|---|
| Challenge | <i>Should describe the status quo, indicate/indication what is still lacking, why this is the case and what negative consequences this has.</i> |
| Objective | <i>Should indicate what exactly should be done to address the challenge in terms of specific actions</i> |
| Outcome | <i>Should describe how the situation will have improved once the actions described in the objectives have been successfully implemented.</i> |

Online Consultation with the 1st set of 47 ToA was performed (12/22)

Structure of the Consultation

The Triplets of Action (ToA) were presented in 4 categories:

- Personalised Medicine related research (ToA numbers 1.1 - 1.17)
- Innovation System and Personalised Medicine (ToA numbers 2.1 - 2.8)
- Personalised Medicine Implementation Setting (ToA numbers 3.1 - 3.16)
- Overarching Activities (ToA numbers 4.1 - 4.6)

Contribution to the consultation:

- Validation and urgency of the presented ToAs
- Selection of 5 most important ToAs per section
- Selection of 5 most important ToAs considering all 47 ToAs
 - How 15M€ would be distributed amongst the selected 5 ToAs
- Possibility to propose new or refine presented ToAs

Online Consultation with the 1st set of 47 ToA was performed (12/22)

Outcome of the Consultation

First outcomes presented today

Consultation report will be published soon (in preparation)


General statistics

Open consultation was open from 21 November – 31 December 2022

Prepared by EP PerMed Drafting Group, disseminated via ICPeMed and ERA PerMed webpages and social media, special ICPeMed newsletter, emails to ICPeMed bodies (ExCom, AB, SHF) and to ICPeMed related CSA coordinators, through national channels and by EC


- Number of interested viewers: 714
- Number of submitted and analysed surveys: 129
- Participants from 21 countries

Stakeholder groups




Summary of analyses

Feedback to the different categories



n=129

Agreement to the ToAs of the different categories



Ranking of ToAs per category


| | | |
|----------------------------------|--|-----|
| Research (n=110) | Triplet of Action 1.1 “A collaborative approach between pre-clinical and clinical research” | 72% |
| | Triplet of Action 1.7 “New targets for personalised therapies making use of an improved understanding of disease mechanisms” | 55% |
| Innovation System (n=61) | Triplet of Action 2.5 “Early cooperation between public research and the private sector” | 75% |
| | Triplet of Action 2.1 “Expanded knowledge on value for PM” | 61% |
| Implementation Setting (n=61) | Triplet of Action 3.3 “Training and Education of healthcare professionals” | 51% |
| | Triplet of Action 3.2 “Test Beds in hospitals” | 41% |
| Overarching Activities (n=62) | Triplet of Action 4.5 “Network of national and regional innovation hubs” | 84% |
| | Triplet of Action 4.3 “Connected large-scale health databases” | 82% |

| |
|------------------------|
| Research |
| Innovation System |
| Implementation Setting |
| Overarching Activities |


Top-ranked ToAs over all categories

| | | |
|---------|----------|--|
| Group 1 | ToA 1.1 | A collaborative approach between pre-clinical and clinical research |
| | ToA 1.7 | New targets for Personalised therapies making use of an improved understanding of disease mechanisms |
| | ToA 1.6 | More biomarker evidence for PM |
| Group 2 | ToA 1.9 | Single-cell technologies in combination with AI and ML for PM |
| | ToA 4.5 | Network of national and regional innovation hubs |
| | ToA 1.11 | Medical cohorts for collecting high-quality health and molecular data |
| | ToA 1.3 | New treatment modalities for PM |
| | ToA 2.5 | Early cooperation between public research and the private sector |
| Group 3 | ToA 4.3 | Connected large-scale health databases |
| | ToA 1.10 | Broader biomarker approaches to enable more informed health decisions |
| | ToA 1.5 | Active involvement of patients in PM research |

Mean budget allocated to the 10 favoured ToAs



Sum of budget allocated by the participants



Note: first ToA of Category 3 Implementation followed on place 13/11: ToA 3.2 with 32 Mio. € in total and a mean budget allocated of 3.27Mio. €

Suggestions for new ToAs

| |
|--|
| Early detection of non-communicable disease |
| Improvement of patients' adherence to therapy |
| Predictive patient-derived disease models for PM* |
| Technology Platforms for accelerating and de-risking of Advanced Therapy Medicinal Product (ATMP) innovations** |
| Need to promote equity in PM clinical studies |
| Improve equity in health and wellbeing across individuals and groups |
| High-throughput high-content profiling workflows for early stage evaluation of safety / toxicity (and off-target reactivity) of drug candidates |

| |
|-------------------------------|
| Research |
| Innovation System |
| Implementation Setting |
| Overarching Activities |

**10x nominated, **2x nominated*

- In addition 10 ideas/topics for ToAs were provided but not elaborated
- Suggestions for adaptations of 13 ToAs

European Partnership for Personalised Medicine - EP PerMed

Strategic Research and Innovation Agenda (SRIA) – content development – this workshop

- Additional support for the SRIA development and EP PerMed activities by this workshop
- The workshop is the last input for the SRIA development before its finalisation by the Drafting Group
- We are looking forward to fruitful discussions in the panels and active participation of all workshop participants

Thank you for your attention

You are also welcome to contact us or other representatives of the SRIA Drafting Group or the proposal Writing Group in the case of questions!

Contact: EPPerMed@dlr.de

Monika Frenzel (ANR, France) and

Wolfgang Ballensiefen (DLR, Germany)